Chicago, IL (PRWEB) February 26, 2014 -- The birth control safety center at DrugRisk.com is announcing updated information on the site for patients who’ve taken the drugs Yaz or Yasmin. Recent court documents show the number of pending lawsuits alleging the drugs caused blood clot injuries has dropped slightly for February*.
DrugRisk is a free resource offering the latest news, safety alerts, product recalls and litigation updates to those taking popular prescription drugs. Visitors can find out if others are experiencing similar side effects, avoid potential dangers and decide if they need legal advice.
The resource center has added health warnings from experts including the British Medical Journal** and FDA*** that birth control pills like Yaz and Yasmin containing the hormone drospirenone can increase the risk of blood clots.
The U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) also recently ordered doctors to warn patients taking certain birth control like Yasmin that they are nearly twice as likely to develop blood clots****.
A number of women have filed a Yaz lawsuit alleging side effects like blood clots, leading cases to be consolidated to a special federal court (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)).
Now, DrugRisk has learned the latest court records show the number of pending cases has dropped slightly for February to 9,687, down from 9,781 on January 15th*. Bayer has spent nearly $1.575 billion so far to settle around 7,660 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*****.
Anyone who suffered a blood clot, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin, or with questions about the ongoing settlements, is urged to visit DrugRisk or speak with a lawyer about their legal options.
Due to the specialized nature of federal drug injury litigation, DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*JPML, 2/19/14; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-February-19-2014.pdf
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****British Journal of Family Medicine, Feb 2014; bjfm.co.uk/content/article.aspx?id=25769806997
*****Bayer Stockholder’s Newsletter, Explanatory Notes; Legal Risks, 10/31/13; stockholders-newsletter-q3-2013.bayer.com/en/explanatory-notes.aspx
Chris Schroeder, DrugRisk, http://www.DrugRisk.com, +1 888-415-1859, [email protected]
Share this article